JP4575670B2 - 3−ヘテロアリール−3,5−ジヒドロ−4−オキソ−4H−ピリダジノ[4,5−b]インドール−1−アセトアミド誘導体、それらの製造、および治療におけるそれらの適用 - Google Patents

3−ヘテロアリール−3,5−ジヒドロ−4−オキソ−4H−ピリダジノ[4,5−b]インドール−1−アセトアミド誘導体、それらの製造、および治療におけるそれらの適用 Download PDF

Info

Publication number
JP4575670B2
JP4575670B2 JP2003580339A JP2003580339A JP4575670B2 JP 4575670 B2 JP4575670 B2 JP 4575670B2 JP 2003580339 A JP2003580339 A JP 2003580339A JP 2003580339 A JP2003580339 A JP 2003580339A JP 4575670 B2 JP4575670 B2 JP 4575670B2
Authority
JP
Japan
Prior art keywords
sub
mmol
compound
group
indole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003580339A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005527566A5 (cg-RX-API-DMAC10.html
JP2005527566A (ja
Inventor
フロイッサント,ジャックス
マラブ,ブノワ
マーゲット,フランク
プエヒ,フレデリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of JP2005527566A publication Critical patent/JP2005527566A/ja
Publication of JP2005527566A5 publication Critical patent/JP2005527566A5/ja
Application granted granted Critical
Publication of JP4575670B2 publication Critical patent/JP4575670B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
JP2003580339A 2002-04-03 2003-04-02 3−ヘテロアリール−3,5−ジヒドロ−4−オキソ−4H−ピリダジノ[4,5−b]インドール−1−アセトアミド誘導体、それらの製造、および治療におけるそれらの適用 Expired - Fee Related JP4575670B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0204158A FR2838124B1 (fr) 2002-04-03 2002-04-03 Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-acetamide, leur preparation et leur application en therapeutique
PCT/FR2003/001027 WO2003082874A2 (fr) 2002-04-03 2003-04-02 DERIVES DE 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO[4,5-b]INDOLE-1-ACETAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010141683A Division JP5277208B2 (ja) 2002-04-03 2010-06-22 3−ヘテロアリール−3,5−ジヒドロ−4−オキソ−4H−ピリダジノ[4,5−b]インドール−1−アセトアミド誘導体、それらの製造、および治療におけるそれらの適用

Publications (3)

Publication Number Publication Date
JP2005527566A JP2005527566A (ja) 2005-09-15
JP2005527566A5 JP2005527566A5 (cg-RX-API-DMAC10.html) 2006-05-25
JP4575670B2 true JP4575670B2 (ja) 2010-11-04

Family

ID=28052083

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003580339A Expired - Fee Related JP4575670B2 (ja) 2002-04-03 2003-04-02 3−ヘテロアリール−3,5−ジヒドロ−4−オキソ−4H−ピリダジノ[4,5−b]インドール−1−アセトアミド誘導体、それらの製造、および治療におけるそれらの適用
JP2010141683A Expired - Fee Related JP5277208B2 (ja) 2002-04-03 2010-06-22 3−ヘテロアリール−3,5−ジヒドロ−4−オキソ−4H−ピリダジノ[4,5−b]インドール−1−アセトアミド誘導体、それらの製造、および治療におけるそれらの適用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010141683A Expired - Fee Related JP5277208B2 (ja) 2002-04-03 2010-06-22 3−ヘテロアリール−3,5−ジヒドロ−4−オキソ−4H−ピリダジノ[4,5−b]インドール−1−アセトアミド誘導体、それらの製造、および治療におけるそれらの適用

Country Status (28)

Country Link
US (4) US7235554B2 (cg-RX-API-DMAC10.html)
EP (1) EP1492792B1 (cg-RX-API-DMAC10.html)
JP (2) JP4575670B2 (cg-RX-API-DMAC10.html)
KR (1) KR100975999B1 (cg-RX-API-DMAC10.html)
CN (2) CN100406459C (cg-RX-API-DMAC10.html)
AT (1) ATE321763T1 (cg-RX-API-DMAC10.html)
AU (1) AU2003240930B2 (cg-RX-API-DMAC10.html)
BR (1) BR0309018A (cg-RX-API-DMAC10.html)
CA (1) CA2481460C (cg-RX-API-DMAC10.html)
CY (1) CY1104998T1 (cg-RX-API-DMAC10.html)
DE (1) DE60304327T2 (cg-RX-API-DMAC10.html)
DK (1) DK1492792T3 (cg-RX-API-DMAC10.html)
EA (1) EA007219B1 (cg-RX-API-DMAC10.html)
ES (1) ES2261940T3 (cg-RX-API-DMAC10.html)
FR (1) FR2838124B1 (cg-RX-API-DMAC10.html)
HR (1) HRP20040911B1 (cg-RX-API-DMAC10.html)
IL (2) IL164257A0 (cg-RX-API-DMAC10.html)
IS (1) IS2483B (cg-RX-API-DMAC10.html)
ME (2) MEP23708A (cg-RX-API-DMAC10.html)
MX (1) MXPA04009635A (cg-RX-API-DMAC10.html)
NO (1) NO329426B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ535741A (cg-RX-API-DMAC10.html)
PL (1) PL372617A1 (cg-RX-API-DMAC10.html)
PT (1) PT1492792E (cg-RX-API-DMAC10.html)
RS (1) RS51244B (cg-RX-API-DMAC10.html)
UA (1) UA77273C2 (cg-RX-API-DMAC10.html)
WO (1) WO2003082874A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200407945B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006017932A1 (en) * 2004-08-18 2006-02-23 Genesense Technologies Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
JP2009504752A (ja) * 2005-08-19 2009-02-05 シェーリング コーポレイション 治療剤としての縮合三環式mGluR1アンタゴニスト
US20120041211A1 (en) * 2009-01-30 2012-02-16 Sythana Suresh Kumar Novel process for preparing carboxy-containing pyrazoleamido compounds 597
CN105330665B (zh) * 2015-11-04 2017-10-03 衡阳师范学院 一种抑制激肽释放酶klk7的化合物、制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754262B1 (fr) * 1996-10-08 1998-10-30 Synthelabo Derives de 1h-pyrido[3,4-b]indole-4-carboxamide, leur preparation et leur application en therapeutique
FR2766823B1 (fr) * 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
FR2788776B1 (fr) * 1999-01-26 2001-02-23 Synthelabo Derives de 4-oxo-3, 5-dihydro-4h-pyridazino [4,5-b] indole-1 -carboxamide, leur preparation et leur application en therapeutique
FR2811897A1 (fr) * 2000-07-24 2002-01-25 Sanofi Synthelabo UTILISATION DE DERIVES DE PYRIDAZINO[4,5-b]INDOLE-1- ACETAMIDE POUR LA PREPARATION DE MEDICAMENTS DESTINES AU TRAITEMENT DES DYSFONCTIONNEMENTS DES RECEPTEURS DE TYPE PERIPHERIQUE AUX BENZODIAZEPINES
FR2811990A1 (fr) * 2000-07-24 2002-01-25 Sanofi Synthelabo DERIVES DE 1-(4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b]INDOLE-1 -CARBONYL)PIPERAZINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2833953B1 (fr) * 2001-12-21 2004-12-03 Sanofi Synthelabo DERIVES DE 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO [4,5-b]INDOLE-1-CARBOXAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Also Published As

Publication number Publication date
IS7478A (is) 2004-09-30
AU2003240930B2 (en) 2009-07-30
RS51244B (sr) 2010-12-31
KR20040094904A (ko) 2004-11-10
NO329426B1 (no) 2010-10-18
EP1492792B1 (fr) 2006-03-29
US7405306B2 (en) 2008-07-29
US7235554B2 (en) 2007-06-26
KR100975999B1 (ko) 2010-08-17
CA2481460A1 (en) 2003-10-09
BR0309018A (pt) 2005-02-01
EP1492792A2 (fr) 2005-01-05
HK1074632A1 (zh) 2005-11-18
ES2261940T3 (es) 2006-11-16
UA77273C2 (en) 2006-11-15
EA007219B1 (ru) 2006-08-25
JP2010248221A (ja) 2010-11-04
NZ535741A (en) 2007-03-30
DE60304327D1 (de) 2006-05-18
WO2003082874A2 (fr) 2003-10-09
JP2005527566A (ja) 2005-09-15
CN1656099A (zh) 2005-08-17
DK1492792T3 (da) 2006-08-14
DE60304327T2 (de) 2006-12-28
JP5277208B2 (ja) 2013-08-28
HK1102371A1 (en) 2007-11-16
US20070219202A1 (en) 2007-09-20
CN100406459C (zh) 2008-07-30
MXPA04009635A (es) 2005-07-13
PT1492792E (pt) 2006-08-31
MEP23708A (en) 2010-06-10
IS2483B (is) 2008-12-15
FR2838124B1 (fr) 2004-05-28
US7323467B2 (en) 2008-01-29
ZA200407945B (en) 2005-11-30
CN100543016C (zh) 2009-09-23
US20050124615A1 (en) 2005-06-09
CA2481460C (en) 2011-02-15
US20080076775A1 (en) 2008-03-27
CY1104998T1 (el) 2009-11-04
NO20044153L (no) 2004-12-27
HRP20040911A2 (en) 2004-12-31
US20080255129A1 (en) 2008-10-16
HRP20040911B1 (en) 2012-11-30
WO2003082874A3 (fr) 2004-04-01
PL372617A1 (en) 2005-07-25
CN1970538A (zh) 2007-05-30
EA200401146A1 (ru) 2005-06-30
ME00081B (me) 2010-10-10
AU2003240930A1 (en) 2003-10-13
FR2838124A1 (fr) 2003-10-10
ATE321763T1 (de) 2006-04-15
IL164257A (en) 2009-11-18
IL164257A0 (en) 2005-12-18
RS86904A (sr) 2006-12-15

Similar Documents

Publication Publication Date Title
JP5277208B2 (ja) 3−ヘテロアリール−3,5−ジヒドロ−4−オキソ−4H−ピリダジノ[4,5−b]インドール−1−アセトアミド誘導体、それらの製造、および治療におけるそれらの適用
JP5087204B2 (ja) 3−ヘテロアリール−3,5−ジヒドロ−4−オキソ−4H−ピリダジノ[4,5−b]インドール−1−カルボキシアミド誘導体、それらの製造および治療的使用
JP4909889B2 (ja) 2h−又は3h−ベンゾ[e]インダゾール1−イルカルバメート誘導体、これらの調製及び治療的使用
US20090215741A1 (en) 1H-Pyrimido[4,5-b]indole Derivatives, Their Preparation and Therapeutic Use
HK1074632B (en) 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments
HK1102371B (en) Intermediate compound of 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives
MXPA06009859A (en) 2h or 3h-benzo[e]indazol-1-yle carbamate derivatives, the preparation and therapeutic use thereof
HK1065792B (en) 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-carboxamide derivatives, their preparation and therapeutic use
HK1104288B (en) 2h or 3h-benzo[e]indazol-1-yle carbamate derivatives, the preparation and therapeutic use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100622

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100721

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100817

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100820

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130827

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees